Cargando…

Perspectives on the clinical development of immunotherapy in prostate cancer

Despite impressive survival benefits with immunotherapy in patients with various solid tumors, the full potential of these agents in prostate cancer has yet to be realized. Sipuleucel-T demonstrated a survival benefit in this population, indicating that prostate cancer is an immunoresponsive disease...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cordes, Lisa M, Gulley, James L, Madan, Ravi A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2018
Materias:	Invited Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5952479/ https://www.ncbi.nlm.nih.gov/pubmed/29582792 http://dx.doi.org/10.4103/aja.aja_9_18

Ejemplares similares

Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications
por: Singh, B Harpreet, et al.
Publicado: (2014)

Developing immunotherapy strategies in the treatment of prostate cancer
por: Gulley, James L., et al.
Publicado: (2016)

The path forward in prostate cancer therapeutics
por: Aragon-Ching, Jeanny B, et al.
Publicado: (2018)

Perspectives on the clinical management of localized prostate cancer
por: Nelson, Joel B
Publicado: (2014)

Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment
por: Gulley, James L., et al.
Publicado: (2017)

Current perspectives of the Japanese Esophageal Oncology Group on the development of immunotherapy for esophageal cancer
por: Kadono, Toru, et al.
Publicado: (2022)

Avelumab in Men With Metastatic Castration-Resistant Prostate Cancer, Enriched for Patients Treated Previously With a Therapeutic Cancer Vaccine
por: Madan, Ravi A., et al.
Publicado: (2023)

Poxviral-based vaccine elicits immunologic responses in prostate cancer patients
por: Madan, Ravi A, et al.
Publicado: (2014)

Clinical validity and utility of genetic risk scores in prostate cancer
por: Helfand, Brian T, et al.
Publicado: (2016)

Current and emerging trends in prostate cancer immunotherapy
por: Schatz, Adam, et al.
Publicado: (2019)

Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer
por: Madan, Ravi A, et al.
Publicado: (2021)

Global developments in prostate cancer research and clinical practice
por: Miyahira, Andrea K, et al.
Publicado: (2014)

Current issues and perspectives in PD-1 blockade cancer immunotherapy
por: Chamoto, Kenji, et al.
Publicado: (2020)

Immunotherapy: Shifting the Balance of Cell-Mediated Immunity and Suppression in Human Prostate Cancer
por: Tucker, Jo A., et al.
Publicado: (2012)

Clinical variability and molecular heterogeneity in prostate cancer
por: Shoag, Jonathan, et al.
Publicado: (2016)

Prostate cancer epigenetics and its clinical implications
por: Yegnasubramanian, Srinivasan
Publicado: (2016)

New developments in the treatment of castration resistant prostate cancer
por: Wadia, Roxanne, et al.
Publicado: (2014)

Engineered biomaterials for cancer immunotherapy
por: Cai, Lulu, et al.
Publicado: (2020)

Recent progress and perspectives on prostate cancer biomarkers
por: Hatakeyama, Shingo, et al.
Publicado: (2016)

Epigenetic regulation of prostate cancer: the theories and the clinical implications
por: Liao, Yiji, et al.
Publicado: (2019)

Antifungal chemotherapies and immunotherapies for the future
por: Armstrong‐James, Darius
Publicado: (2022)

Glucocorticoids and prostate cancer treatment: friend or foe?
por: Montgomery, Bruce, et al.
Publicado: (2014)

Long-Term Survival and PSA Control with Radiation and Immunotherapy for Node Positive Prostate Cancer
por: Kamrava, M., et al.
Publicado: (2009)

Long noncoding RNAs in prostate cancer: overview and clinical implications
por: Malik, Bhavna, et al.
Publicado: (2016)

Exploiting Synergy: Immune-Based Combinations in the Treatment of Prostate Cancer
por: Burotto, Mauricio, et al.
Publicado: (2014)

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma
por: McNeel, Douglas G., et al.
Publicado: (2016)

Metabolism in tumor microenvironment: Implications for cancer immunotherapy
por: Shi, Rongchen, et al.
Publicado: (2020)

Vitamin D in prostate cancer
por: Trump, Donald L, et al.
Publicado: (2018)

DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer
por: Liu, Wennuan
Publicado: (2016)

Update of early phase clinical trials in cancer immunotherapy
por: Lee, Dae Ho
Publicado: (2021)

Testosterone therapy in men with prostate cancer: literature review, clinical experience, and recommendations
por: Morgentaler, Abraham, et al.
Publicado: (2015)

T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance
por: Chandran, Smita S., et al.
Publicado: (2019)

A Perspective of Immunotherapy for Prostate Cancer
por: Silvestri, Ida, et al.
Publicado: (2016)

Immune metabolism in PD-1 blockade-based cancer immunotherapy
por: Kumar, Alok, et al.
Publicado: (2020)

Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm
por: Gulley, James L., et al.
Publicado: (2015)

Role of chemotherapy in prostate cancer
por: Nader, Rita, et al.
Publicado: (2018)

Prostate cancer stem cells
por: Lang, SH, et al.
Publicado: (2009)

Highlights of the 31st annual meeting of the Society for Immunotherapy of Cancer (SITC), 2016
por: Gulley, James L., et al.
Publicado: (2017)

Multiple therapeutic and preventive effects of 3,3′-diindolylmethane on cancers including prostate cancer and high grade prostatic intraepithelial neoplasia
por: Zhang, William Weiben, et al.
Publicado: (2014)

Multiparametric Magnetic Resonance Imaging for Active Surveillance of Prostate Cancer
por: An, Julie Y., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8usc5f51l39m41pvavsdusmqk2